2024-03-29T07:55:28Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/55232023-02-27T14:22:27Zcom_20.500.12105_2145com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2146
Repisalud
author
Becerra, Virginia
author
Gracia, Alfredo
author
Desai, Kamal
author
Abogunrin, Seye
author
Brand, Sarah
author
Chapman, Ruth
author
Garcia Alonso, Fernando
author
Fuster, Valentin
author
Sanz, Gines
funder
Ferrer
2017-12-01T07:37:27Z
2017-12-01T07:37:27Z
2015
BMJ Open. 2015; 5(5):e007111
2044-6055
http://hdl.handle.net/20.500.12105/5523
25991449
10.1136/bmjopen-2014-007111
BMJ Open
Objective: To evaluate the public health and economic benefits of adherence to a fixed-dose combination polypill for the secondary prevention of cardiovascular (CV) events in adults with a history of myocardial infarction (MI) in the UK. Design: Markov-model-based cost-effectiveness analysis, informed by systematic reviews, which identified efficacy, utilities and adherence data inputs. Setting: General practice in the UK. Participants: Patients with a mean age of 64.7 years, most of whom are men with a recent or non-recent diagnosis of MI and for whom secondary preventive medication is indicated and well tolerated. Intervention: Fixed-dose combination polypill (100 mg aspirin, 20 mg atorvastatin and 2.5, 5, or 10 mg ramipril) compared with multiple monotherapy. Primary and secondary outcome measures: CV events prevented per 1000 patients; cost per life-year gained; and cost per quality-adjusted life-year (QALY) gained. Results: The model estimates that for each 10\% increase in adherence, an additional 6.7\% fatal and non-fatal CV events can be prevented. In the base case, over 10 years, the polypill would improve adherence by similar to 20\% and thereby prevent 47 of 323 (15\%) fatal and non-fatal CV events per 1000 patients compared with multiple monotherapy, with an incremental cost-effectiveness ratio (ICER) of 8200 pound per QALY gained. Probabilistic sensitivity analyses for the base-case assumptions showed an 81.5\% chance of the polypill being cost-effective at a willingness-to-pay threshold of 20 pound 000 per QALY gained compared with multiple monotherapy. In scenario analyses that varied structural assumptions, ICERs ranged between cost saving and 21 pound 430 per QALY gained. Conclusions: Assuming that some 450 000 adults are at risk of MI, a 10 percentage point uptake of the polypill could prevent 3260 CV events and 590 CV deaths over a decade. The polypill appears to be a cost-effective strategy to prevent fatal and non-fatal CV events in the UK.
eng
PERCUTANEOUS CORONARY INTERVENTION
ACUTE MYOCARDIAL-INFARCTION
HIGH-RISK
HEART-DISEASE
COMBINATION TREATMENT
ECONOMIC-EVALUATION
ARTERY-DISEASE
EUROASPIRE III
PRIMARY-CARE
LIFE-STYLE
Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
journal article
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5523/1/Cost-effectivenessAndPublicHealth_2015.pdf
File
MD5
f82aea6a7d46744084a5f95e42628077
843419
application/pdf
Cost-effectivenessAndPublicHealth_2015.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5523/2/Cost-effectivenessAndPublicHealth_2015_CM.pdf
File
MD5
9c26b163d0022ae2a00c0d209bc20258
886536
application/pdf
Cost-effectivenessAndPublicHealth_2015_CM.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5523/9/Cost-effectivenessAndPublicHealth_2015.pdf.txt
File
MD5
573ce5ab2ecea84b0826ad3d83f23e4c
53303
text/plain
Cost-effectivenessAndPublicHealth_2015.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5523/11/Cost-effectivenessAndPublicHealth_2015_CM.pdf.txt
File
MD5
ba5f6e7cc6460c4beb5b8ac45ca99472
57248
text/plain
Cost-effectivenessAndPublicHealth_2015_CM.pdf.txt